Orion Corporation: Orion Corporation is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and market Finland (FI)

Notice NOT-AA-19-016 from the NIH Guide for Grants and Contracts

Notice NOT-AA-19-018 from the NIH Guide for Grants and Contracts

Notice NOT-AA-19-017 from the NIH Guide for Grants and Contracts

Notice NOT-CA-19-052 from the NIH Guide for Grants and Contracts

Notice NOT-DA-19-045 from the NIH Guide for Grants and Contracts

Notice NOT-HL-19-700 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-19-287 from the NIH Guide for Grants and Contracts. The National Cancer Institutes (NCI) Cancer Systems Biology Consortium (CSBC) supports systems biology approaches to cancer research and includes U54 CSBC Research Centers, a U24 CSBC Coordinating Center and, through this FOA, well-defined, discrete and circumscribed U01 Research Projects. CSBC Research Projects are expected to involve interdisciplinary teams of scientists, engineers, and cancer researchers who collaborate to advance our understanding of the mechanisms underlying cancer initiation, progression, and treatment. CSBC Research Projects proposed in response to this Funding Opportunity Announcement must demonstrate explicit integration of experimental biology and computational modeling to test and validate novel hypotheses in cancer research.

Funding Opportunity RFA-AG-20-043 from the NIH Guide for Grants and Contracts. This funding opportunity will support a new, centralized infrastructure (U24) to aggregate, harmonize, manage, and share existing and future neuroimaging data collected in NIA- supported Alzheimer's Disease Research Centers (ADRCs).

Funding Opportunity RFA-DA-20-001 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIDA/NIMH R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs in the use of ABCD data. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on courses for skills development, particularly short-term workshops that will allow participants to explore the hands-on use of ABCD data, through cooperative or competitive approaches.

Notice NOT-AA-19-019 from the NIH Guide for Grants and Contracts

Notice NOT-DA-19-047 from the NIH Guide for Grants and Contracts

Provide statistical and computational tools for biologically based activities such as genetic analysis, measurement of gene expression, and gene function... $60,000 - $200,000 a year
From selfdecode.com - Wed, 22 May 2019 04:09:31 GMT - View all Ellsworth, WI jobs

Provide statistical and computational tools for biologically based activities such as genetic analysis, measurement of gene expression, and gene function... $60,000 - $200,000 a year
From selfdecode.com - Tue, 21 May 2019 22:04:09 GMT - View all Milwaukee, WI jobs

Competitive Salary: University of Nebraska Medical Center: The Dept. of Genetics, Cell Biology and Anatomy seeks an Assistant/Associate Professor with expertise in ‘Bioinformatics and Human Microbiome’. Omaha, Nebraska

Notice NOT-AA-19-015 from the NIH Guide for Grants and Contracts

Notice NOT-DA-19-044 from the NIH Guide for Grants and Contracts

Notice NOT-HL-19-695 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-GM-19-001 from the NIH Guide for Grants and Contracts. Human induced pluripotent stem cells (iPSCs) have been used with great success to mimic the differentiation of a variety of tissues, understand early development and study human diseases. Despite approaches that have made the derivation, growth and differentiation of iPSCs more efficient, there remains significant variability in reprogramming efficacy, genomic integrity and developmental potential of iPSCs derived from a single fibroblast or tissue sample. Thus, iPSCs derived from the same sample may differ in their in vitro growth characteristics and their ability to re-differentiate into the desired tissue type. A variety of issues may affect derivation of the iPSCs and their growth, stability and differentiation, including the specific characteristics of the starting cell or tissue sample (e.g., age of donor, tissue type and anatomical location, physiological and disease state), the methods and protocols used to induce pluripotency (e.g., transcription factors, small molecules, cell fusion), the choice of growth factors and other culture conditions, method of storage of cell lines, etc. Further challenges include growing and maintaining sufficient quantities of iPSC lines in culture without changes in their properties, as well as the ability of multiple investigators to identify and authenticate iPSC lines as part of their research. This Funding Opportunity Announcement (FOA) will support SBIR projects to develop novel, reliable and cost-effective methods to standardize and increase the utility and reproducibility of iPSCs at all stages, from their derivation to their research and clinical applications.

Notice NOT-OD-19-108 from the NIH Guide for Grants and Contracts